UNAIDS Series: Engaging uniformed services in the fight against AIDS - Case Study 1
Fighting AIDS
WHO Annual Meeting with Pharmaceutical Companies and Stakeholders
08 March 2016, Geneva
2015-06-03 - Board presentation - v32.pptx
USAID Office of HIV/AIDS
March 8-9, 2016
Int J Health Policy Manag 2017, 6(10), 587–600
Low-income countries face many contextual challenges to manage healthcare technologies effectively, as the majority are imported and resources are constrained to a greater extent. Previous healthcare technology management (HTM) policies in Benin ha...ve failed to produce better quality of care for the population and cost-effectiveness for the government. This study aims to identify and assess the main problems facing HTM in Benin’s public health sector, as well as the ability of key actors within the sector to address these problems.
more
PQDx 0179-012-00 WHO
PQDx Public Report
June/2017, version 4.0
PQDx 0144-043-00 WHO
PQDx Public Report
November/2016, version 4.0
Product:BDFACSCountTM InstrumentSystemwithFACSCountTM ControlKitandBD FACSCountTM CD4ReagentKit(AbsoluteandPercentageCD4+Counts)
Number: PQDx 0133-045-00
0133-045-00 WHO
PQDx PR
June/2016, version 2.0
PQDx 0027-012-00 WHO
PQDx Public Report
May/2017, version 4.0
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
Vision 2030
Accessed: 17.11.2019
Policy
July 2012
Working Paper No. 3
Policy Brief
HIV testing services
December 2016
WHO/HIV/2016.21
HIV testing services
Policy Brief
December 2016
HIV testing services
Policy Brief
November 2018
WHO/CDS/HIV/18.48
The primary role of Benin’s Department of Pharmacy and Medicines (DPMED) is to develop and apply the national pharmaceutical policy. The main objective of this policy is to ensure the availability and accessibility of quality medicines for the population. To fulfill its mandate, DPMED aims to stre...ngthen its regulatory capacity, including the issuance of licenses to pharmaceutical establishments and the registration of pharmaceutical products. Benin’s current registration system shares core concerns that are common to most developing countries, notably the capacity to evaluate and monitor the security, efficacy, and quality of medicines and other health products. It is currently characterized by 1) poor or inadequate traceability of records or regulations (example: a product’s marketing authorization [MA] is often hard to find); 2) lack of evidence used in the regulatory decision-making process (reasons behind special import authorization, i.e., products without valid MAs); 3) inconsistent and unsecured archiving system; 4) limited human resources; and 5) an inefficient information management system
more
UNAIDS | 2016–2021 Strategy
Accessed: 20.11.2019
Stories of putting people at the centre
Accessed: 20.11.2019
Original Research
Rev Panam Salud Publica 43, 2019 | www.paho.org/journal | https://doi.org/10.26633/RPSP.2019.31